CG Oncology believes that the Phase III data for its oncolytic immunotherapy for bladder cancer show that cretostimogene grenadenorepvec can spare patients bladder surgery, and analysts said the data could position it as a best-in-class therapy for high-risk non-muscle invasive bladder cancer (NMIBC) compared to a competing Phase III candidate from Johnson & Johnson, as well as Merck & Co.’s Keytruda (pembrolizumab).
CG Oncology Is Building A Best-In-Class Profile In NMIBC
Cretostimogene Phase III Data Look Competitive
The biotech’s Phase III data with an oncolytic immunotherapy for non-muscle invasive bladder cancer shows high complete response rates, duration of response and good safety/tolerability.
More from Advanced Therapies
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus